Researchers in the U.S. have developed a microchip designed to find and capture very small numbers of cancer cells, a task that is notoriously difficult because these cells can be vastly outnumbered by healthy ones. The work comes from a team at Brigham and Women’s Hospital, working with collaborators including MIT, and was reported in the Proceedings of the National Academy of Sciences. At the heart of the device is a three-dimensional DNA network, essentially a mesh of long DNA strands engineered to recognize and latch onto specific targets. Built on a microfluidic surface, meaning a chip that manipulates tiny volumes of fluid through small channels, the system is meant to improve how rare cells are detected and isolated. The researchers say the same basic design could extend beyond cancer to other hard-to-find biological targets, including fetal cells, viruses, and bacteria. That makes the platform potentially useful not just for diagnosis, but also for studying disease and tailoring treatment. While the report describes a research-stage device rather than a commercial product, it points to a broader shift in medicine toward tools that can pull meaningful signals from extremely sparse samples. If the approach holds up in further testing, it could help clinicians detect disease earlier and give scientists a better way to study the biology of rare cells.
How the chip works
The new device relies on DNA not as genetic material, but as a programmable building material. The team created long DNA strands with repetitive sequences, allowing the strands to form a three-dimensional network with many places where target cells can bind.
That matters because rare cancer cells are easy to miss when a sample contains millions of other cells. By giving the surface many repeated targeting sites, the chip increases the odds that a passing cancer cell will stick long enough to be detected and captured.
Why a DNA network is useful
Traditional capture surfaces often depend on a relatively flat coating of molecules that recognize a target. A 3D DNA mesh offers more depth and more contact points, which can improve the ability to snag cells that are present in tiny numbers.
The researchers also emphasized that the DNA could be customized. By adjusting features such as strand length and sequence, they could tune the network to go after different cell types or other biological particles, making the platform more flexible than a one-purpose chip.
The microfluidic advantage
The chip is built on a microfluidic surface, a technology that controls the movement of fluids at a very small scale. In practice, that means a blood or tissue sample can be guided across a specially prepared surface in a controlled way, improving the chances that rare targets will encounter the DNA network.
Microfluidics has become a cornerstone of modern bioengineering because it can handle tiny sample volumes with high precision. For rare-cell detection, that precision is especially important: when the targets are scarce, the system has to make every interaction count.
Who developed it
According to the report, the study was led by Dr. Jeffrey Karp of the Division of Biomedical Engineering in the Department of Medicine at Brigham and Women’s Hospital. The work also involved Prof. Rohit Karnik of the Massachusetts Institute of Technology.
The collaboration reflects a familiar pattern in biomedical device development. Hospital researchers bring the clinical problem—how to find cells that are present in vanishingly small amounts—while engineers contribute the materials design and fluid-handling strategies needed to build a practical chip.
Potential uses beyond cancer
Although the headline focus is cancer, the authors described a wider range of possible applications. Because the DNA network can be engineered to recognize different targets, the same platform could potentially be adapted to capture fetal cells, as well as infectious agents such as viruses and bacteria.
That versatility is important because rare-cell and rare-particle capture is a common bottleneck across medicine. Whether the goal is prenatal testing, infection detection, or cancer monitoring, researchers often face the same technical challenge: pulling a tiny signal from a noisy biological background.
What the study suggests
The publication in PNAS signals that the work has passed peer review and is being presented as a meaningful technical advance. From the details available, the key contribution is not just that the chip can bind cancer cells, but that it does so using a rapidly generated DNA architecture with multiple targeting sites.
That combination could make the device easier to adapt than systems that require a completely new surface chemistry for each target. In other words, the real value may lie in the platform concept: a reusable way to design capture chips for many different diagnostic problems.
Why This Matters
In cancer care, earlier and more precise detection can change what treatment options are available. If doctors can isolate very small populations of cancerous cells from a sample, they may be able to detect disease sooner, monitor whether therapy is working, or study how a tumor changes over time.
For researchers, captured rare cells are also a source of valuable information. Once isolated, those cells can be examined for genetic or molecular clues that explain why a cancer spreads, resists drugs, or returns after treatment.
What comes next
The report describes a promising research tool, but more work would be needed before it becomes part of routine clinical testing. Future studies will likely need to show how well the chip performs with real patient samples, how reliably it distinguishes target cells from non-target cells, and how easily it can be manufactured at scale.
Even so, the idea is compelling: use DNA as a smart, customizable capture net on a microfluidic chip to pull rare biological targets out of a complex sample. As diagnostics move toward less invasive and more information-rich testing, technologies like this could become an important bridge between engineering innovation and everyday medical care.